BACKGROUND: Essential @entity844 supplementation has been found to ameliorate certain chronic inflammatory diseases. This effect is thought to be mediated through the modulation of eicosanoid synthesis. Pro-inflammatory @entity1813 have been implicated in @entity31 . AIM: To investigate the possible therapeutic benefit of essential @entity1718 in quiescent @entity31 to reduce the frequency of disease relapse. METHODS: A randomized, double-blind, placebo-controlled study was performed with a treatment duration of 12 months. @entity1 with quiescent disease received either trial medication ( @entity18943 , 1.6 g, @entity7784 , 270 mg, and @entity4600 , 45 mg, per day) or placebo (sunflower oil, 500 mg/day). The primary end-point was disease activity, assessed by a previously validated clinical index, sigmoidoscopic appearance and histology. RESULTS: Sixty-three @entity1 were randomized, 31 to receive essential @entity844 treatment and 32 to receive placebo. Disease relapse rates were similar at 12 months (placebo, 38%; essential @entity1718 , 55%), as were changes in sigmoidoscopic grade from baseline. CONCLUSIONS: The supplementation of the diet with this combination of essential @entity1718 does not prolong the period of disease remission of @entity31 .

A double-blind, randomized, placebo-controlled trial of essential XXXX supplementation in the maintenance of remission of @entity31 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity7784 :: ('MESH:D015118', 'Chemical') :: ['eicosapentaenoic acid'] @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid'] @entity4600 :: ('CHEBI:28125', 'Chemical') :: ['docosahexaenoic acid'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity18943 :: ('MESH:D017965', 'Chemical') :: ['gamma-linolenic acid'] @entity1813 :: ('MESH:D015777', 'Chemical') :: ['eicosanoids'] @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']
@entity844 :: (CHEBI:35366,Chemical) :: ['fatty acid']
